Hôpital Archet 2
- Address
- lock Available on a paid plan
Digestive System Diseases – Crohn's disease
The gastroenterology team at Hôpital Archet 2 is conducting research aimed at reducing postoperative recurrence of Crohn's disease by testing a new therapeutic agent and refining endoscopic assessment methods.
- Evaluation of the novel biologic EXL01 for disease control
- Use of endoscopic modified Rutgeerts scores to monitor treatment response
- Strategies to prevent post‑surgical disease flare‑ups
With a team of 10 investigators, the site is advancing personalized care for patients with inflammatory bowel disease in Nice, France.
Neoplasms – Ewing Sarcoma
In the oncology division, researchers are exploring ways to improve outcomes for newly diagnosed metastatic Ewing Sarcoma by integrating targeted agents, maintenance chemotherapy, and optimized radiotherapy protocols.
- Adding regorafenib to standard VDC/IE chemotherapy
- Assessing maintenance regimens of vinorelbine and cyclophosphamide
- Investigating radiotherapy dose escalation for inoperable tumors
- Comparing post‑operative radiotherapy dose levels for optimal control
The collaborative effort of 10 investigators at this French research centre seeks to set new standards for sarcoma treatment across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 13 of 15 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Archet 2
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Dexmedetomidine vs Placebo on Cumulative Opioid Consumption in Premature Neonates Receiving Invasive Mechanical Ventilation: A Randomized Controlled Trial | Centre Hospitalier Intercommunal Creteil | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 2 | Unknown | 2022-05-30 | 2025-09-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.